|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dai X, Mao Z, Huang J, Xie S and Zhang H:
The CXCL12/CXCR4 autocrine loop increases the metastatic potential
of non-small cell lung cancer in vitro. Oncol Lett. 5:277–282.
2013.PubMed/NCBI
|
|
7
|
Xie S, Zeng W, Fan G, Huang J, Kang G,
Geng Q, Cheng B, Wang W and Dong P: Effect of CXCL12/CXCR4 on
increasing the metastatic potential of non-small cell lung cancer
in vitro is inhibited through the downregulation of CXCR4 chemokine
receptor expression. Oncol Lett. 7:941–947. 2014.PubMed/NCBI
|
|
8
|
Wang T, Mi Y, Pian L, Gao P, Xu H, Zheng Y
and Xuan X: RNAi targeting CXCR4 inhibits proliferation and
invasion of esophageal carcinoma cells. Diagn Pathol. 8:1042013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nikzaban M, Hakhamaneshi MS, Fakhari S,
Sheikhesmaili F, Roshani D, Ahsan B, Kamali F and Jalili A: The
chemokine receptor CXCR4 is associated with the staging of gastric
cancer. Adv Biomed Res. 3:162014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Teng F, Tian WY, Wang YM, Zhang YF, Guo F,
Zhao J, Gao C and Xue FX: Cancer-associated fibroblasts promote the
progression of endometrial cancer via the SDF-1/CXCR4 axis. J
Hematol Oncol. 9:82016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kishima M Okuyama, de Oliveira CE,
Banin-Hirata BK, Losi-Guembarovski R, Brajão de Oliveira K,
Amarante MK and Watanabe MA: Immunohistochemical expression of
CXCR4 on breast cancer and its clinical significance. Anal Cell
Pathol (Amst). 2015:8910202015.PubMed/NCBI
|
|
12
|
Nakamura T, Shinriki S, Jono H, Guo J,
Ueda M, Hayashi M, Yamashita S, Zijlstra A, Nakayama H, Hiraki A,
et al: Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is
crucial for drug resistance and a slow-cycling state in bone
marrow-disseminated tumor cells. Oncotarget. 6:1008–1019. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Jiang K, Qiu X, Li M, Hao Q, Wei L,
Zhang W, Chen B and Xin X: Overexpression of CXCR4 is significantly
associated with cisplatin-based chemotherapy resistance and can be
a prognostic factor in epithelial ovarian cancer. BMB Rep.
47:33–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rousseaux S, Debernardi A, Jacquiau B,
Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY,
Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and
placental genes identifies aggressive metastasis-prone lung
cancers. Sci Transl Med. 5:186ra66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sato M, Larsen JE, Lee W, Sun H, Shames
DS, Dalvi MP, Ramirez RD, Tang H, DiMaio JM, Gao B, et al: Human
lung epithelial cells progressed to malignancy through specific
oncogenic manipulations. Mol Cancer Res. 11:638–650. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Riquelme E, Suraokar M, Behrens C, Lin HY,
Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, et al:
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma
cells and EZH2 depletion enhances the response to platinum-based
and VEGFR-2-targeted therapy. Clin Cancer Res. 20:3849–3861. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang I, Mitsui Y, Fukuhara S, Gill A,
Wong DK, Yamamura S, Shahryari V, Tabatabai ZL, Dahiya R, Shin DM,
et al: Loss of miR-200c up-regulates CYP1B1 and confers docetaxel
resistance in renal cell carcinoma. Oncotarget. 6:7774–7787. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hendrikx JJ, Lagas JS, Rosing H, Schellens
JH, Beijnen JH and Schinkel AH: P-glycoprotein and cytochrome P450
3A act together in restricting the oral bioavailability of
paclitaxel. Int J Cancer. 132:2439–2447. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kudo T, Ozaki Y, Kusano T, Hotta E, Oya Y,
Komatsu S, Goda H and Ito K: Effect of buffer conditions on
CYP2C8-mediated paclitaxel 6alpha-hydroxylation and CYP3A4-mediated
triazolam alpha- and 4-hydroxylation by human liver microsomes.
Xenobiotica. 46:241–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laroche-Clary A, Le Morvan V, Yamori T and
Robert J: Cytochrome P450 1B1 gene polymorphisms as predictors of
anticancer drug activity: Studies with in vitro models. Mol Cancer
Ther. 9:3315–3321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pastina I, Giovannetti E, Chioni A,
Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci
S, et al: Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with
response to docetaxel in castration-resistant prostate cancer
(CRPC) patients. BMC Cancer. 10:5112010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vasile E, Tibaldi C, Leon GL, D'Incecco A
and Giovannetti E: Cytochrome P450 1B1 (CYP1B1) polymorphisms are
associated with clinical outcome of docetaxel in non-small cell
lung cancer (NSCLC) patients. J Cancer Res Clin Oncol.
141:1189–1194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wen CJ, Wu LX, Fu LJ, Shen DY, Zhang X,
Zhang YW, Yu J and Zhou HH: Preferential induction of CYP1A1 over
CYP1B1 in human breast cancer MCF-7 cells after exposure to
berberine. Asian Pac J Cancer Prev. 15:495–499. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu X, Zhang XA and Wang DW: The roles of
CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in
cardiovascular and malignant diseases. Adv Drug Deliv Rev.
63:597–609. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu Z, Mu Y, Qi C, Wang J, Xi G, Guo J, Mi
R and Zhao F: CYP1B1 enhances the resistance of epithelial ovarian
cancer cells to paclitaxel in vivo and in vitro. Int J Mol Med.
35:340–348. 2015.PubMed/NCBI
|
|
26
|
Chen Z, Teo AE and McCarty N: ROS-induced
CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival
and drug resistance in the bone marrow microenvironment via
autophagy. Clin Cancer Res. 22:187–199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y, Miao H, Li W, Yao J, Sun Y, Li Z,
Zhao L and Guo Q: CXCL12/CXCR4 axis confers adriamycin resistance
to human chronic myelogenous leukemia and oroxylin A improves the
sensitivity of K562/ADM cells. Biochem Pharmacol. 90:212–225. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Luca A, D'Alessio A, Gallo M, Maiello
MR, Bode AM and Normanno N: Src and CXCR4 are involved in the
invasiveness of breast cancer cells with acquired resistance to
lapatinib. Cell Cycle. 13:148–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang M, Chen GY, Song HT, Hong X, Yang ZY
and Sui GJ: Significance of CXCR4, phosphorylated STAT3 and VEGF-A
expression in resected non-small cell lung cancer. Exp Ther Med.
2:517–522. 2011.PubMed/NCBI
|
|
30
|
Al Zobair AA, Al Obeidy BF, Yang L, Yang
C, Hui Y, Yu H, Zheng F, Yang G, Xie C, Zhou F, et al: Concomitant
overexpression of EGFR and CXCR4 is associated with worse prognosis
in a new molecular subtype of non-small cell lung cancer. Oncol
Rep. 29:1524–1532. 2013.PubMed/NCBI
|
|
31
|
Sison EA, Magoon D, Li L, Annesley CE, Rau
RE, Small D and Brown P: Plerixafor as a chemosensitizing agent in
pediatric acute lymphoblastic leukemia: Efficacy and potential
mechanisms of resistance to CXCR4 inhibition. Oncotarget.
5:8947–8958. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sankhwar M, Sankhwar SN, Abhishek A, Gupta
N and Rajender S: CYP1B1 gene polymorphisms correlate with an
increased risk of urinary bladder cancer in India. Urol Oncol.
34:167. e161–168. 2016. View Article : Google Scholar
|
|
33
|
Yu PJ, Chen WG, Feng QL, Chen W, Jiang MJ
and Li ZQ: Association between CYP1B1 gene polymorphisms and risk
factors and susceptibility to laryngeal cancer. Med Sci Monit.
21:239–245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Patel SA, Bhambra U, Charalambous MP,
David RM, Edwards RJ, Lightfoot T, Boobis AR and Gooderham NJ:
Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in
colorectal cancer involves DNA methylation, miR27b and STAT3. Br J
Cancer. 111:2287–2296. 2014. View Article : Google Scholar : PubMed/NCBI
|
